Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use

References

• Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 113, 179–189. https://doi.org/10.1016/j.neubiorev.2020.03.017
   PubMed Web of Science ®Google Scholar
• Apud, I. (2016). Pharmacology of consciousness or pharmacology of spirituality? A historical review of psychedelic clinical studies. Journal of Transpersonal Psychology, 48(2), 150–167.
   Google Scholar
• Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M.S, Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279–1295. https://doi.org/10.1177/0269881116678781
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019
   PubMed Web of Science ®Google Scholar
• Baumeister, R. F., & Placidi, K. S. (1983). A social history and analysis of the LSD controversy. Journal of Humanistic Psychology, 23(4), 25–58. https://doi.org/10.1177/0022167883234003
   Web of Science ®Google Scholar
• Blaine, B., & Crocker, J. (1995). Religiousness, race, and psychological well-being: Exploring social psychological mediators. Personality & Social Psychology Bulletin, 21(10), 1031–1041. https://doi.org/10.1177/01461672952110004
   Web of Science ®Google Scholar
• Bogenschutz, M. P., & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, 250–258. https://doi.org/10.1016/j.pnpbp.2015.03.002
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2020). Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology, 237(8), 2293–2304. https://doi.org/10.1007/s00213-020-05533-9
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Fielding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1007/s00213-017-4771-x
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., & Nutt, D. J. (2010). User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use, 15(4), 283–300. https://doi.org/10.3109/14659890903271624
   Web of Science ®Google Scholar
• Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725–731. https://doi.org/10.1177/0269881118754710
   PubMed Web of Science ®Google Scholar
• Chandler, J., Rosenzweig, C., Moss, A. J., Robinson, J., & Litman, L. (2019). Online panels in social science research: Expanding sampling methods beyond Mechanical Turk. Behavior Research Methods, 51(5), 2022–2038. https://doi.org/10.3758/s13428-019-01273-7
   PubMed Web of Science ®Google Scholar
• Davis, A. K., Clifton, J. M., Weaver, E. G., Hurwitz, E. S., Johnson, M. W., & Griffiths, R. R. (2020). Survey of entity encounter experiences occasioned by inhaled -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. Journal of Psychopharmacology, 34(9), 1008–1020. https://doi.org/10.1177/0269881120916143
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. (2020). 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe. https://www.deadiversion.usdoj.gov/drug_chem_info/nbome.pdf
   Google Scholar
• Exline, J. J., Pargament, K. I., Grubbs, J. B., & Yali, A. M. (2014). The Religious and Spiritual Struggles Scale: Development and initial validation. Psychology of Religion and Spirituality, 6(3), 208–222. https://doi.org/10.1037/a0036465
   Web of Science ®Google Scholar
• Exline, J. J., Pargament, K. I., Wilt, J. A., & Harriott, V. A. (2021). Mental illness, normal psychological processes, or attacks by the devil? Three lenses to frame demonic struggles in therapy. Spirituality in Clinical Practice, 8(3), 215–228. https://doi.org/10.1037/scp0000268
   Web of Science ®Google Scholar
• Exline, J. J., & Wilt, J. A. (in press). Supernatural attributions: Seeing God, the devil, demons, spirits, fate, and karma as causes of events. Annual Review of Clinical Psychology.
   Google Scholar
• Exline, J. J., Wilt, J. A., Stauner, N., Schutt, W. A., Pargament, K. I., Fincham, F., & May, R. W. (2021). Supernatural operating rules: How people envision and experience God, the devil, ghosts/spirits, fate/destiny, karma, and luck. Psychology of Religion and Spirituality. Advance online publication. https://doi.org/10.1037/rel0000444
   Web of Science ®Google Scholar
• Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793
   PubMed Web of Science ®Google Scholar
• Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy, 87. N.PAG–N.PAG. https://doi.org/10.1016/j.drugpo.2020.102997
   Google Scholar
• González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S. C., & Gingrich, J. A. (2007). Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron, 53(3), 439–452. https://doi.org/10.1016/j.neuron.2007.01.008
   PubMed Web of Science ®Google Scholar
• Griffiths, R., Hurwitz, E. S., Davis, A. K., Johnson, M. W., & Jesse, R. (2019). Survey of subjective “god encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One, 14(4), e0214377. https://doi.org/10.1371/journal.pone.0214377
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Griffiths, R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5
   PubMed Web of Science ®Google Scholar
• Hartogsohn I. (2018). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Frontiers in Neuroscience, 12 https://doi.org/10.3389/fnins.2018.00129
   PubMed Web of Science ®Google Scholar
• Hoffmann, A. (2017). LSD, my problem child: Reflections on sacred drugs, mysticism, and science (4th ed.). McNaughton & Gunn.
   Google Scholar
• Hood, R. W., Jr., Ghorbani, N., Watson, P. J., Ghramaleki, A. F., Bing, M. N., Davison, H. K., Morris, R. J., & Williamson, W. P. (2001). Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. Journal for the Scientific Study of Religion, 40(4), 691–705. https://doi.org/10.1111/0021-8294.00085
   Web of Science ®Google Scholar
• Huxley, A. (1956). Heaven and hell. Harper & Brothers.
   Google Scholar
• Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010
   PubMed Web of Science ®Google Scholar
• Johnstad, P. G. (2021). Day trip to hell: A mixed methods study of challenging psychedelic experiences. Journal of Psychedelic Studies, 5(2), 114–127. https://doi.org/10.1556/2054.2021.00155
   Google Scholar
• Leary, T., Metzner, R., & Alpert, R. (1964). The psychedelic experience: A manual based on the Tibetan book of the dead. University Books.
   Google Scholar
• Luke, D. (2011). Discarnate entities and dimethyltryptamine (DMT): Psychopharmacology, phenomenology, and ontology. Journal of the American Society of Psychical Research, 75(1), 26–42.
   Google Scholar
• Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Zarandi, S. S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
   PubMed Web of Science ®Google Scholar
• Martial, C., Cassol, H., Charland-Verville, V., Pallavicini, C., Sanz, C., Zamberlan, F., Vivot, R. M., Erowid, F., Erowid, E., Laureys, S., Greyson, B., & Tagliazucchi, E. (2019). Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports. Consciousness & Cognition, 69, 52–69. https://doi.org/10.1016/j.concog.2019.01.011
   PubMed Web of Science ®Google Scholar
• Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 67(11), 1735–1740. https://doi.org/10.4088/jcp.v67n1110
   PubMed Web of Science ®Google Scholar
• Nayak, S. M., Singh, M., Yaden, D. B. and Griffiths, R. R. (2022). Belief changes associated with psychedelic use. Journal of Psychopharmacology, 026988112211319 https://doi.org/10.1177/02698811221131989
   Web of Science ®Google Scholar
• Neitzke-Spruill, L., & Glasser, C. (2018). A gratuitous grace: The influence of religious set and intent on the psychedelic experience. Journal of Psychoactive Drugs, 50(4), 314–321. https://doi.org/10.1080/02791072.2018.1494869
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
   PubMed Web of Science ®Google Scholar
• Olson, D. E. (2018). Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience, 12, 1179069518800508. https://doi.org/10.1177/1179069518800508
   Web of Science ®Google Scholar
• Olson, D. E. (2020). The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology and Translational Science, 4(2), 563–567. https://doi.org/10.1021/acsptsci.0c00192
   PubMedGoogle Scholar
• Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418–434. https://doi.org/10.1111/j.1749-6632.1957.tb40738.x
   PubMed Web of Science ®Google Scholar
• Pargament, K. I., & Exline, J. J. (2022). Working with spiritual struggles in psychotherapy: From research to practice. Guilford.
   Google Scholar
• Pargament, K. I., Mahoney, A., Exline, J. J., Jones, J. W., & Shafranske, E. P. (2013). Envisioning an integrative paradigm for the psychology of religion and spirituality: An introduction to the APA handbook of psychology, religion and spirituality. In K. I. Pargament, J. J. Exline, & J. W. Jones (Eds.), APA handbook of psychology, religion, and spirituality (Vol. 1, pp. 3–19). American Psychological Association.
   Google Scholar
• Pollan, M. (2018). How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. Penguin.
   Google Scholar
• Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and psychedelic-assisted psychotherapy. The American Journal of Psychiatry, 177(5), 391–410. https://doi.org/10.1176/appi.ajp.2019.19010035
   PubMed Web of Science ®Google Scholar
• Ruck, C. A., Bigwood, J., Staples, D., Ott, J., & Wasson, R. G. (1979). Entheogens. Journal of Psychedelic Drugs, 11(1–2), 145–146. https://doi.org/10.1080/02791072.1979.10472098
   PubMed Web of Science ®Google Scholar
• Shanon, B. (2002). The antipodes of the mind: Charting the phenomenology of the ayahuasca experience. Oxford.
   Google Scholar
• Stenbæk, D. S., Madsen, M. K., Ozenne, B., Kristiansen, S., Burmester, D., Erritzoe, D., Fisher, P. M., Knudsen, G.M., & Fisher, P. M. (2021). Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 35(4), 459–468. https://doi.org/10.1177/0269881120959609
   PubMed Web of Science ®Google Scholar
• Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. The Journal of Nervous and Mental Disease, 172(10), 577–595. https://doi.org/10.1097/00005053-198410000-00001
   PubMed Web of Science ®Google Scholar
• Strassman, R. J. (1991). Human hallucinogenic drug research in the United States: A present-day case history and review of the process. Journal of Psychoactive Drugs, 23(1), 29–38. https://doi.org/10.1080/02791072.1991.10472572
   PubMed Web of Science ®Google Scholar
• Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E. and Carhart-Harris, R. L. (2021). Psychedelics alter metaphysical beliefs. Scientific Reports, 11(1 22166), https://doi.org/10.1038/s41598-021-01209-2
   PubMed Web of Science ®Google Scholar
• Yaden, D. B., & Griffiths, R. R. (2021). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology and Translational Science, 4(2), 568–572. https://doi.org/10.1021/acsptsci.0c00194
   PubMedGoogle Scholar
• Yaden, D. B., Le Nguyen, K. D., Kern, M. L., Belser, A. B., Eichstaedt, J. C., Iwry, J., Smith, M. E., Wintering, N. A., Hood, R. W., & Newberg, A. B. (2017). Of roots and fruits: A comparison of psychedelic and nonpsychedelic mystical experiences. Journal of Humanistic Psychology, 57(4), 338–353. https://doi.org/10.1177/0022167816674625
   Web of Science ®Google Scholar